Physician profile
Michael Gredzik
NPI 1023593936
$903.99
in general payments reported to CMS, 2019-2025
10 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.82 · 2021: $207 · 2022: $41.51 · 2023: $91.16 · 2024: $249 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $630.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $267.93 | 2021-2025 | Total30, Dailies Total1 |
| Abbvie INC. | $202.91 | 2024-2025 | |
| Bausch & Lomb Americas INC. | $147.80 | 2024 | Envista Mx60 Iol, Infuse |
| Tarsus Pharmaceuticals, INC. | $113.88 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $60.30 | 2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $49.69 | 2020-2021 | |
| Harrow Eye, LLC | $18.00 | 2025 | Vevye |
| Johnson & Johnson Vision Care, INC. | $16.51 | 2025 | |
| Oyster Point Pharma, INC. | $13.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gredzik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.